DOET

Hypertension, Arrhythmia, Cardiac valve disease, Heart failure

DOET produces blood pressure elevation and hyperthermia via serotonergic cardiovascular mechanisms confirmed in rodent models. The DOx class shows high correlation between 5-HT₂A and 5-HT₂B affinities, implicating theoretical cardiac valvulopathy risk under sustained exposure. No clinical case data exist for DOET, but the pharmacological basis is established at the class level.

Epilepsy, Seizure disorders

Serotonergic psychedelics as a class carry a theoretical risk of lowering seizure threshold. No DOET-specific seizure data exist. This relative contraindication is inferred from the serotonergic psychedelic class.

Schizophrenia, Schizoaffective disorder, Bipolar disorder, Severe anxiety disorders

As a serotonergic psychedelic acting through 5-HT₂A receptors, DOET carries the class-level risk of precipitating or exacerbating psychotic episodes, manic episodes, or severe anxiety in psychiatrically vulnerable individuals. No DOET-specific psychiatric adverse event data exist; this contraindication is inferred from the serotonergic psychedelic class. The 14–20-hour duration amplifies psychological risk through prolonged vulnerability.

Hepatic impairment, Liver cirrhosis, Severe hepatic dysfunction

DOET is presumed to undergo CYP2D6-mediated O-demethylation based on structural analogy to DOC. Significant hepatic impairment could impair drug clearance, prolonging the already extreme 14–20-hour duration and intensifying effects. No clinical data inform this contraindication; it is inferred entirely from the metabolic pathway.

Pregnancy, Lactation

No reproductive toxicity, teratogenicity, or lactation safety data exist for DOET. The compound is contraindicated during pregnancy and lactation as a precautionary measure based on its pharmacological class — a serotonergic psychedelic with documented cardiovascular stimulant properties.

MAOI use, Concurrent serotonergic medication

Concurrent use of monoamine oxidase inhibitors with DOET risks pharmacodynamic serotonergic potentiation and additive cardiovascular stimulation. Unlike tryptamines, DOx compounds are primarily CYP2D6-metabolized, so the pharmacokinetic interaction with MAOIs may be less severe. However, the combination of MAOI-elevated monoamine levels with a 5-HT₂A agonist carrying sympathomimetic cardiovascular properties remains potentially dangerous. No DOET-specific MAOI interaction data exist.